(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > Clínica Universidad de Navarra > Oftalmología > DA - CUN - Oftalmología - Artículos de revista >

Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion
Autor(es) : Salinas-Alaman, A. (Ángel)
Zarranz-Ventura, J. (Javier)
Caire-Gonzalez-Jauregui, J.M. (José M.)
Sadaba-Echarri, L.M. (Luis M.)
Barrio-Barrio, J. (Jesús)
Garcia-Layana, A. (Alfredo)
Palabras clave : Angiogenesis inhibitors/administration and dosage
Antibodies, monoclonal, humanized/administration and dosage
Fecha incorporación: 2011
Editorial : Wichtig Editore
Versión del editor: http://dx.doi.org/10.5301/EJO.2010.6101
ISSN: 1120-6721
Cita: Salinas-Alaman A, Zarranz-Ventura J, Caire Gonzalez-Jauregui JM, Sadaba-Echarri LM, Barrio-Barrio J, Garcia-Layana A. Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 2011 Jul-Aug;21(4):434-439.
Resumen
To evaluate intravitreal bevacizumab (IVB) combined with grid laser photocoagulation in macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: Eight eyes (8 patients) with ME associated with BRVO with at least 3 months of evolution since symptom onset were included. All subjects underwent measurement of best-corrected visual acuity (BCVA) and imaging with spectral domain optical coherence tomography (SD-OCT) at baseline and 1, 3, 6, and 12 months. Intravitreal bevacizumab was administered at baseline and macular grid laser photocoagulation 1 month later. During follow-up, additional IVB was administered based on physician discretion if persistent or recurrent intraretinal fluid (cysts) was observed on SD-OCT. The mean BCVA and SD-OCT central subfield thickness (CST) values were determined at each time point. Fisher exact test was performed to assess differences between baseline and post-treatment BCVA and SD-OCT measurements. RESULTS: The mean baseline BCVA was 0.28+/-0.14 (mean+/-SD), and the mean CST was 479+/-137 microm. The mean BCVAs at 1, 3, 6, and 12 months were 0.47+/-0.18 (p=0.031), 0.56+/-0.50 (p=0.031), 0.65+/-0.60 (p=0.008), and 0.66+/-0.65 (p=0.016), respectively. The mean CST values at 1, 3, 6, and 12 months were 295+/-60 microm (p=0.008), 333+/-114 microm (p=0.070), 339+/-80 microm (p=0.008), and 335+/-109 microm (p=0.008). A mean 2.13 injections were administered; the second injection was administered a mean of 2.71 months after baseline. CONCLUSIONS: Combined treatment with IVB and macular grid photocoagulation provided good results and may be considered as an alternative therapy for ME in BRVO. Further studies are needed to assess these preliminary results.
Enlace permanente: http://hdl.handle.net/10171/22445
Aparece en las colecciones: DA - Medicina - Oftalmología - Artículos de revista
DA - CUN - Oftalmología - Artículos de revista

Ficheros en este registro:
Fichero:  Eur J Ophthalmol 2011. 434.pdf
Descripción: 
Tamaño:  231,43 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.